Download PDF

1. Company Snapshot

1.a. Company Description

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.It also provides second opinion consultation and health care decision support services.


The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs.Accolade, Inc.was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.

Show Full description

1.b. Last Insights on ACCD

Accolade, Inc.'s recent performance was driven by its acquisition by Transcarent for $7.03 per share in cash, announced on January 8, 2025. This news led to a significant increase in Accolade's stock price, with shares trading over 100% higher on January 9, 2025. The acquisition provides a premium to Accolade's recent stock price, indicating a positive development for shareholders. Additionally, the acquisition eliminates the need for Accolade to pursue further cost-cutting measures, such as share buybacks, which would have also positively impacted shareholders.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

TalkingParents Takes Home 11th Accolade For Support Network Initiative

Aug -12

Source: globenewswire.com

Card image cap

The One Show Announces Historic Win: Klick Health Becomes First Health Agency to Ever Receive An Agency of the Year Accolade

May -16

Source: businesswire.com

Card image cap

Wellspring Launches Next-Gen Innovation Platform, Accolade Core

May -08

Source: globenewswire.com

Card image cap

Pernod completes sale of wine portfolio to Accolade Wines owner

Apr -30

Source: reuters.com

Card image cap

Digital health startup Transcarent takes Accolade private in $621 million deal

Apr -08

Source: cnbc.com

Card image cap

Transcarent Completes Merger With Accolade

Apr -08

Source: businesswire.com

Card image cap

Accolade Stockholders Approve Merger Between Accolade and Transcarent

Mar -27

Source: globenewswire.com

Card image cap

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

Mar -06

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.78%)

6. Segments

Access Fees

Expected Growth: 13.5%

Accolade, Inc.'s 13.5% growth in Access Fees is driven by increasing adoption of its personalized health and benefits solutions, expansion into new markets, and strategic partnerships with healthcare providers and employers. Additionally, the company's data-driven approach and AI-powered platform have improved customer engagement, leading to higher utilization rates and revenue growth.

Utilization-based Fees

Expected Growth: 14.5%

Accolade's 14.5% growth in utilization-based fees is driven by increasing adoption of value-based care models, expansion of existing client relationships, and growth in the number of lives managed. Additionally, the company's data-driven approach and personalized health and benefits experience are contributing to higher engagement and improved health outcomes, resulting in increased fees.

7. Detailed Products

Accolade One-on-One

Personalized health and benefits advocacy platform that connects members with dedicated health assistants

Accolade Care

Comprehensive care management platform that provides personalized support for members with chronic conditions

Accolade Engagement

Behavioral health and wellness platform that encourages healthy habits and self-care

Accolade Analytics

Data analytics platform that provides insights into healthcare utilization and cost trends

Accolade Expert Medical Opinion

Independent medical opinion service that provides expert diagnoses and treatment plans

8. Accolade, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Accolade, Inc. is medium, as there are some alternatives available in the market, but they are not very attractive to customers.

Bargaining Power Of Customers

The bargaining power of customers for Accolade, Inc. is low, as customers have limited options and the company has a strong brand presence.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Accolade, Inc. is medium, as the company relies on a few key suppliers, but they do not have a high level of bargaining power.

Threat Of New Entrants

The threat of new entrants for Accolade, Inc. is high, as the industry is attractive and there are low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry for Accolade, Inc. is high, as the industry is highly competitive and there are many players competing for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 32.61%
Debt Cost 3.95%
Equity Weight 67.39%
Equity Cost 14.50%
WACC 11.06%
Leverage 48.39%

11. Quality Control: Accolade, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Accolade

A-Score: 4.6/10

Value: 8.0

Growth: 5.8

Quality: 3.8

Yield: 0.0

Momentum: 9.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
OptimizeRx

A-Score: 4.3/10

Value: 3.5

Growth: 6.0

Quality: 5.2

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Health Catalyst

A-Score: 3.6/10

Value: 9.2

Growth: 5.6

Quality: 4.3

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Schrödinger

A-Score: 3.4/10

Value: 4.6

Growth: 2.8

Quality: 3.9

Yield: 0.0

Momentum: 7.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Teladoc Health

A-Score: 3.4/10

Value: 6.7

Growth: 5.1

Quality: 3.2

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Augmedix

A-Score: 3.2/10

Value: 6.4

Growth: 4.6

Quality: 3.5

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.02$

Current Price

7.02$

Potential

-0.00%

Expected Cash-Flows